FDA Approves KYGEVVI, the First and Only Treatment for Adults and Children Living With Thymidine Kinase 2 Deficiency, a Rare and Devastating Mitochondrial Disease
November 04, 2025
November 04, 2025
CHICAGO, Illinois, Nov. 4 -- The Muscular Dystrophy Association issued the following news release on Nov. 3, 2025:
* * *
FDA Approves KYGEVVI (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease
This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes progressive mus . . .
* * *
FDA Approves KYGEVVI (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease
This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes progressive mus . . .